Show simple item record

A phase I study of ABT-510 plus bevacizumab in advanced solid tumors.

dc.contributor.author Uronis, Hope E
dc.contributor.author Cushman, Stephanie M
dc.contributor.author Bendell, Johanna C
dc.contributor.author Blobe, Gerard C
dc.contributor.author Morse, Michael A
dc.contributor.author Nixon, Andrew B
dc.contributor.author Dellinger, Andrew
dc.contributor.author Starr, Mark D
dc.contributor.author Li, Haiyan
dc.contributor.author Meadows, Kellen
dc.contributor.author Gockerman, Jon
dc.contributor.author Pang, Herbert
dc.contributor.author Hurwitz, Herbert I
dc.coverage.spatial United States
dc.date.accessioned 2015-12-04T13:20:51Z
dc.date.issued 2013-06
dc.identifier http://www.ncbi.nlm.nih.gov/pubmed/23930208
dc.identifier.uri https://hdl.handle.net/10161/11086
dc.description.abstract Targeting multiple regulators of tumor angiogenesis have the potential to improve treatment efficacy. Bevacizumab is a monoclonal antibody directed against vascular endothelial growth factor and ABT-510 is a synthetic analog of thrombospondin, an endogenous angiogenesis inhibitor. Dual inhibition may result in additional benefit. We evaluated the safety, tolerability, and efficacy of the combination of bevacizumab plus ABT-510 in patients with refractory solid tumors. We also explored the effects of these agents on plasma-based biomarkers and wound angiogenesis. Thirty-four evaluable subjects were enrolled and received study drug. Therapy was well tolerated; minimal treatment-related grade 3/4 toxicity was observed. One patient treated at dose level 1 had a partial response and five other patients treated at the recommended phase II dose had prolonged stable disease for more than 1 year. Biomarker evaluation revealed increased levels of D-dimer, von Willebrand factor, placental growth factor, and stromal-derived factor 1 in response to treatment with the combination of bevacizumab and ABT-510. Data suggest that continued evaluation of combination antiangiogenesis therapies may be clinically useful.
dc.language eng
dc.publisher Wiley
dc.relation.ispartof Cancer Med
dc.relation.isversionof 10.1002/cam4.65
dc.subject ABT-510
dc.subject advanced solid tumors
dc.subject bevacizumab
dc.subject phase I
dc.subject Adult
dc.subject Aged
dc.subject Angiogenesis Inhibitors
dc.subject Antibodies, Monoclonal, Humanized
dc.subject Antineoplastic Combined Chemotherapy Protocols
dc.subject Bevacizumab
dc.subject Dose-Response Relationship, Drug
dc.subject Female
dc.subject Humans
dc.subject Male
dc.subject Middle Aged
dc.subject Neoplasms
dc.subject Oligopeptides
dc.subject Young Adult
dc.title A phase I study of ABT-510 plus bevacizumab in advanced solid tumors.
dc.type Journal article
duke.contributor.id Uronis, Hope E|0265192
duke.contributor.id Blobe, Gerard C|0061626
duke.contributor.id Morse, Michael A|0096084
duke.contributor.id Nixon, Andrew B|0213792
duke.contributor.id Pang, Herbert|0484520
pubs.author-url http://www.ncbi.nlm.nih.gov/pubmed/23930208
pubs.begin-page 316
pubs.end-page 324
pubs.issue 3
pubs.organisational-group Basic Science Departments
pubs.organisational-group Biostatistics & Bioinformatics
pubs.organisational-group Clinical Science Departments
pubs.organisational-group Duke
pubs.organisational-group Duke Cancer Institute
pubs.organisational-group Institutes and Centers
pubs.organisational-group Medicine
pubs.organisational-group Medicine, Medical Oncology
pubs.organisational-group Pharmacology & Cancer Biology
pubs.organisational-group School of Medicine
pubs.organisational-group Surgery
pubs.organisational-group Surgery, Surgical Oncology Molecular Theraputics
pubs.publication-status Published
pubs.volume 2
dc.identifier.eissn 2045-7634
duke.contributor.orcid Blobe, Gerard C|0000-0002-4274-8901
duke.contributor.orcid Nixon, Andrew B|0000-0003-3971-2964


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record